Tesla Turns Shell Gas Station in Spain Into a Sleek Supercharger Hub, Redefining EV Charging 
Arthur Hayes Drives Solana Meme Coin Rally, FlowerAI’s Market Cap Jumps $8M After Social Media Post 
The Key Pros and Cons of iGaming Restrictions for 2025 
Tesla Out of California’s EV Tax Credit Plan? Shocking Exclusion Sparks Debate Over Federal and State Policies 
Benefits of BLDC fans in the monsoon: All you need to know! 
Siri's AI Upgrade in iOS 19 May Signal Apple's Split from OpenAI and ChatGPT 
Cardano Hits $1.06 Milestone as Experts Eye $6 and Beyond in Bullish Breakout 
Crypto Rules Shakeup: Trump-Tied SEC Candidate Hints at Clearer Path After Gensler’s Sudden Exit 
Understanding Self-Exclusion Programs: Your Guide to Responsible Gaming 
Global economic trends shaping local transportation: Insights from the Netherlands 
Shiba Inu Sends Urgent Scam Alert Amid 12% Price Spike: Details Unveiled 
Dogecoin Rockets 25% as Analyst Forecasts Bullish Breakout to $0.82 
OpenAI, Samsung Talks Signal a Major Shift for Galaxy Devices, Threatening Google’s AI Stronghold 
Shiba Inu Whales Dominate Market With $300M in Transactions Despite 9% Price Drop 
TikTok CEO Turns to Musk for Guidance Amid Trump Policy Concerns, WSJ Reports 
Apple Pushes Suppliers for Laptop OLED Displays, Hinting at Soon-to-Launch MacBook Pro Models 
Daewoong Pharmaceuticals struck a deal with Zydus Worldwide DMCC to co-develop anti-cancer injectables in the United States. For this tie-up, the companies signed an agreement worth $92 million.
Korea’s Daewoong and UAE-based Zydus Group aim to market Leuprolide acetate through their licensing deal for the development of a generic of Lupron Depot drug, a leuprolide acetate for depot suspension, that is used for the treatment of advanced prostate cancer, uterine fibroids, and endometriosis. As per The Korea Herald, the former announced its exclusive licensing contract with the latter on Monday, Dec. 11.
Terms of the Deal: Division of Responsibilities
It was stipulated in the agreement that Daewoong would be in charge of preclinical research, studies, production, and supply of the generic called the DWJ108U. The Korean firm shared that it will manufacture the drug at its production plant in Osong, located in North Chungcheong Province.
On the other hand, Zydus will be responsible for all clinical trials and the commercialization of the DWJ108U in the U.S. “Together with Zydus, Daewoong Pharmaceutical will aim to develop and commercialize a generic of AbbVie’s Lupron Depot in the U.S. market,” an official of the Korean pharma company said in a statement.
Contract Period and Payment Agreement
Korea BioMedical Review reported that Daewoong and Zydus agreed to work together for seven years following the first sale. The total value of the licensing deal is about $92.4 million, which will be paid in various forms, including $25.5 million in a commercialization milestone payment and the remaining $66.9 million to be settled soon after the drug’s possible launch in the U.S. market.
Jeon Seng Ho, Daewoong Pharmaceutical’s chief executive officer, said, “Given the complexity, complex generic drug products like Lupron Depot do not exist to date, and we aim to be the first company to manufacture the generic version of this complex, long-acting injectable Lupron Depot product.”
Lastly, Zydus Lifesciences’ managing director, Sharvil Patel, added, “This is an important milestone and we are happy to work with Daewoong for the generic version of Lupron Depot.”
Photo by: Zydus Life Media Kit
